Ask us a question 520 547-3440 info@c-path.org

Subscribe

Home
About
Programs
Sharing Knowledge that Leads to Innovation
ACTIVE CONSORTIA / PROGRAMS

BmDR

Biomarker Data Repository

MSOAC

Multiple Sclerosis Outcome Assessments Consortium

CPAD

Critical Path for Alzheimer’s Disease

PRO Consortium

Patient-Reported Outcome Consortium

CPP

Critical Path for Parkinson’s

PKDOC

Polycystic Kidney Disease Outcomes Consortium

CP-RND

Critical Path for Rare Neurodegenerative Diseases

PredicTox KE

PredicTox Knowledge Environment

CP-SCD

Critical Path for Sickle Cell Disease

PSTC

Predictive Safety Testing Consortium

CPTA

Critical Path to Therapeutics for the Ataxias

QuantMed

Quantitative Medicine Program

CDRC

CURE Drug Repurposing Collaboratory

RDCA-DAP

Rare Disease Cures Accelerator-Data and Analytics Platform

DCC

Data Collaboration Center

RD-COA Consortium

Rare Disease Clinical Outcome Assessment Consortium

D-RSC

Duchenne Regulatory Science Consortium

TB-PACTS

TB-Platform for Aggregation of Clinical TB Studies

eCOA Consortium

Electronic Clinical Outcome Assessment Consortium

TTC

Transplant Therapeutics Consortium

FA-ICD

Friedreich’s Ataxia Integrated Clinical Database

TOMI-T1D

Trial Outcome Markers Initiative in T1D Consortium

HD-RSC

Huntington’s Disease Regulatory Science Consortium

TRxA

Translational Therapeutics Accelerator

INC

International Neonatal Consortium

T1D

Type 1 Diabetes Consortium

Completed Consortia

CFAST

Coalition for Accelerating Standards & Therapies

PTC

Pediatric Trials Consortium

CPTR

Critical Path to TB Drug Regimens
C-Path in Europe
Tools & Platforms
Impact
News & Events
- Events
- News
- Videos
- Publications
- Presentations
- Press Releases
Donate

News

Home>News & Events>Pharmaceutical Industry Members>Actelion Pharmaceuticals Ltd.

News

May 2, 2013 PRINT PDF

Actelion Pharmaceuticals Ltd.

Related Posts

C-Path and Ultragenyx Announce Data Sharing Agreement to Support Rare Disease Treatment and Novel Therapies
eCOA Consortium Announces New Article for Applied Clinical Trials
Drug Repurposing Roadmap that Optimizes Patient Impact through Collaboration
3rd PSTC Japan Safety Biomarker Workshop
Register Now | Shared Stewardship in Collaborative Curation of Rare Disease Datasets

Annual Reports
Contact
Donate
Employment
Explore C-Path
FAQs
FDA Acknowledgement
Policies
GDPR SCCs
Privacy Policy
Terms of Use

C-Path Main Office 1840 E River Rd, Suite 100
Tucson, AZ. 85718
Tel: 520-547-3440
Fax: 520-547-3456 C-Path Global Ltd. 33 Sir John Rogerson’s
Dublin 2, Ireland

Ask us a question Tel: 520-547¬3440
Email: info@c-path.org Subscribe

x